Gruppo Fiaschi
Cellular and Molecular Biology
Coordinator: Tania Fiaschi, Associated Professor – BIOS-08, Molecular Biology
Brief Biographical sketch of the coordinator
- Graduated in Biological Sciences at the University of Florence, Italy.
- Ph.D. in Biochemistry, University of Florence, Italy.
- Degree of post-graduate studies in Biochemistry and Clinical Chemistry, University of Florence, Italy.
Member of the Scientific Board the Doctorate/Ph.D. Program in:
Biomedical Sciences
Member of the following Scientific Societies
The Italian Society of Biophysics and Molecular Biology (SIBBM)
Member of editorial board of the following Journals
Member of the Editorial Board of International Journal of Molecular Sciences (Molecular Biology section)
Member of the Editorial Board of FASEB Journal
Research Team
Francesca Magherini, Associate Professor, Cellular and Applied Biology, BIOS-10/A
Tania Gamberi, Associate Professor, Cellular and Applied Biology, BIOS-10/A
Michele Mannelli, Post-doc
Bartoloni Bianca, Post-doc
Paffetti Caterina, PhD student
Nencioni Elena, PhD student
Current research interest:
Role of cancer microenvironment in cancer cachexia (Tania Fiaschi)
Study of adiponectin in cancer cachexia (Tania Fiaschi)
Cancer cachexia in skeletal muscle and adipose tissue (Tania Fiaschi)
Ovarian cancer: characterization of primary cultures, tumour microenvironment and innovative therapies (Francesca Magherini)
Mechanisms of action/biological targets of metal-based anticancer drugs (Tania Gamberi).
Key words –adiponectin, cancer cachexia, skeletal muscle, ovarian cancer, metal-bases anticancer drug, proteomics
Current/recent sources of funding
2021-AIRC Project code MG26169
10 best publications of the last 5 years
1- Bartoloni B, Mannelli M, Gamberi T, Fiaschi T. The Multiple Roles of Lactate in the Skeletal Muscle. Cells. 2024 Jul 10;13(14):1177
2- Mannelli M, Bartoloni B, Cantini G, Nencioni E, Magherini F, Luconi M, Modesti A, Gamberi T, FiaschiT, STAT3 Signalling Drives LDH Up-Regulation and Adiponectin Down-Regulation in Cachectic Adipocytes. Int J Mol Sci. 2023 Nov 15;24(22):16343.
3- Rojas-Rodríguez M, Fiaschi T, Mannelli M, Mortati L, Celegato F, Wiersma DS, Parmeggiani C, Martella D. Cellular Contact Guidance on Liquid Crystalline Networks with Anisotropic Roughness. ACS Appl Mater Interfaces. 2023 Mar 22;15(11):14122-14130.
4- Mannelli M, Gamberi T, Garella R, Magherini F, Squecco R, Fiaschi T. Pyruvate prevents the onset of the cachectic features and metabolic alterations in myotubes downregulating STAT3 signaling. FASEB J. 2022 Nov;36(11): e22598.
5- Massai L, Messori L, Carpentieri A, Amoresano A, Melchiorre C, Fiaschi T, Modesti A, Gamberi T, Magherini F. The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study. Cancer Chemother Pharmacol. 2022 Jun;89(6):809-823.
6- Bernacchioni C, Squecco R, Gamberi T, Ghini V, Schumacher F, Mannelli M, Garella R, Idrizaj E, Cencetti F, Puliti E, Bruni P, Turano P, Fiaschi T, Donati C. S1P Signalling Axis Is Necessary for Adiponectin-Directed Regulation of Electrophysiological Properties and Oxidative Metabolism in C2C12 Myotubes. Cells. 2022 Feb 17;11(4):713
7- Chiappetta G, Gamberi T, Faienza F, Limaj X, Rizza S, Messori L, Filomeni G, Modesti A, Vinh J. Redox proteome analysis of auranofin exposed ovarian cancer cells (A2780). Redox Biol. 2022 Jun;52:102294.
8- Gamberi T, Chiappetta G, Fiaschi T, Modesti A, Sorbi F, Magherini F. Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness. Med Res Rev. 2022 May;42(3):1111-1146.
9- Martella D, Mannelli M, Squecco R, Garella R, Idrizaj E, Antonioli D, Laus M, Wiersma DS, Gamberi T, Paoli P, Parmeggiani C, Fiaschi T. Cell instructive Liquid Crystalline Networks for myotube formation. iScience. 2021 Sep 2;24(9):103077.
10- Giorgi E, Biver T, Mannelli M, Gamberi T, Becatti M, Sabatino G, Peroni E, Monasson O, Cirri D, Gabbiani C, Pratesi A. Thiosugar-functionalized gold(I)-NHC complexes as selective anticancer agents for potential targeted therapy. Front Chem. 2026 Feb 26; 14:1724206.
Collaborations:
- Michel Abou-Samra, PhD, UCLouvain's Institute of Experimental and Clinical Research (IREC), University of Leuven, Belgium
- Giovanni Chiappetta, PhD, École supérieure de physique et de chimie industrielles de la Ville de Paris, Paris, France
- Paola Braghetta, PhD, Dipartimento di Medicina Molecolare, Università di Padova, Italia
- Roberta Squecco, PhD, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Italia
- Camilla Parmeggiani, PhD, Dipartimento di Chimica 'Ugo Schiff', Università degli Studi di Firenze, Italia
- Daniele Martella, PhD, Istituto Nazionale di Ricerca Metrologica, INRiM
- Luigi Messori, PhD, Dipartimento di Chimica 'Ugo Schiff', Università degli Studi di Firenze, Italia
- Flavia Sorbi, PhD, Dipartimento di Scienze Biomediche, Sperimentali e cliniche “Mario Serio”, Università degli Studi di Firenze, Italia
- Luca Bini. PhD. Dipartimento di Scienze della vita, University of Siena, Italia
- Angela Amoresano, PhD, Dipartimento di Scienze chimiche, Università di Napoli Federico II, Italia
- Paola Turano, PhD, Dipartimento di Chimica 'Ugo Schiff', Università degli Studi di Firenze, Italia
Ultimo aggiornamento
25.03.2026